July 26, 2018

Reva Medical Gains CE Mark for Motiv Below-the-Knee Bioresorbable Scaffold

July 25, 2018—Reva Medical's Motiv drug-eluting bioresorbable scaffold has gained CE Mark approval for application in below-the-knee peripheral artery disease (PAD), the company announced. The Motiv scaffold is made from Tyrocore, a proprietary polymer Reva describes as being inherently radiopaque to ensure accurate placement. Reva's commercial platform also includes the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold.

The company expects initial cases to be performed in late 2018 or early 2019, and it will now select centers to further assess product performance and application while working to determine its complete PAD commercial strategy.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

July 26, 2018

Reva Medical Gains CE Mark for Motiv Below-the-Knee Bioresorbable Scaffold

Current Issue

Keep In Touch